Paper
Efficient synthesis of tert-butyl 3-cyano-3-cyclopropyl-2-oxopyrrolidine-4-carboxylates: Highly functionalized 2-pyrrolidinone enabling access to novel macrocyclic Tyk2 inhibitors.
Published Jan 13, 2020 · Y. Sasaki, Hidekazu Tokuhara, Yusuke Ohba
Bioorganic & medicinal chemistry letters
Q2 SJR score
11
Citations
0
Influential Citations
Abstract
Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.
Study Snapshot
This study presents an efficient method for synthesizing tert-butyl 3-cyano-3-cyclopropyl-2-oxopyrrolidine-4-carboxylate, which led to the identification of a potent and selective macrocyclic Tyk2 inhibitor.
PopulationOlder adults (50-71 years)
Sample size24
MethodsObservational
OutcomesBody Mass Index projections
ResultsSocial networks mitigate obesity in older groups.
Sign up to use Study Snapshot
Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.
Full text analysis coming soon...
References
Identification of Imidazo[1,2-b]pyridazine Derivatives as Potent, Selective, and Orally Active Tyk2 JH2 Inhibitors.
Imidazo[1,2-b]pyridazine derivatives show improved metabolic stability and potency as Tyk2 JH2 inhibitors, with potential for oral administration in treating inflammatory diseases.
2019·37citations·Chunjian Liu et al.·ACS medicinal chemistry letters
ACS medicinal chemistry letters
Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015–2018)
Selective Tyk2 inhibitors show potential as therapeutic agents for treating diseases like psoriasis, systemic lupus erythematosus, inflammatory bowel disease, rheumatoid arthritis, cancer, and diabetes.
2019·60citations·Xingrui He et al.·Expert Opinion on Therapeutic Patents
Expert Opinion on Therapeutic Patents
Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of (( S)-2,2-Difluorocyclopropyl)((1 R,5 S)-3-(2-((1-methyl-1 H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841).
PF-06700841 is a dual JAK1/TYK2 inhibitor that shows potential in treating autoimmune diseases, with potential benefits in psoriasis, psoriatic arthritis, inflammatory bowel disease, and rheumatoid arthritis.
2018·119citations·Andrew Fensome et al.·Journal of medicinal chemistry
Journal of medicinal chemistry
Identification of an imidazopyridine scaffold to generate potent and selective TYK2 inhibitors that demonstrate activity in an in vivo psoriasis model.
Compound 30 shows potential as a therapeutic approach for psoriasis patients by reducing IL-17 production and ear thickness in a mouse model.
2017·19citations·Jun Liang et al.·Bioorganic & medicinal chemistry letters
Bioorganic & medicinal chemistry letters
Biologically active γ-lactams: synthesis and natural sources.
-lactams show broad biological activities and show potential in medicinal chemistry due to their synthesis, natural sources, and diverse biological activities.
2016·145citations·Joséphine Caruano et al.·Organic & biomolecular chemistry
Organic & biomolecular chemistry
Citations
An overview of small-molecule agents for the treatment of psoriasis.
Small-molecule agents targeting various enzymes show promising activity in treating psoriasis, with potential for further development into new anti-psoriasis drugs.
2025·0citations·Zhiheng Jin et al.·Bioorganic & medicinal chemistry
Bioorganic & medicinal chemistry
Tyrosine kinase 2 inhibitors: Synthesis and applications in the treatment of autoimmune diseases.
TYK2 inhibitors show potential in treating autoimmune diseases with reduced side effects and improved therapeutic outcomes.
2024·0citations·Lin Pan et al.·European journal of medicinal chemistry
European journal of medicinal chemistry
Macrocyclization strategy for improving candidate profiles in medicinal chemistry.
Macrocyclization in medicinal chemistry can optimize drug-like properties and efficacy while maintaining bioavailability and permeability, enhancing drug discovery efforts.
2024·4citations·Om Darlami et al.·European journal of medicinal chemistry
European journal of medicinal chemistry
Synthesis and In Vitro Evaluation as Potential Anticancer and Antioxidant Agents of Diphenylamine-Pyrrolidin-2-one-Hydrazone Derivatives
Diphenylamine-pyrrolidin-2-one-hydrazone derivatives show potential as anticancer agents and antioxidants, with four compounds showing the most promising activity against prostate cancer and melanoma cells.
2023·7citations·Irma Zubrickė et al.·International Journal of Molecular Sciences
International Journal of Molecular Sciences
Synthesis and structural determination of pyrrolidine-2,3-dione derivatives from 4-acetyl-3-hydroxy-5-phenyl-1-(3-nitrophenyl)-3-pyrroline-2-one
This study synthesized 1,4,5-trisubstituted pyrrolidine-2,3-diones from 4-acetyl-3-hydroxy-1-(3-nitrophenyl)-3-pyrroline-2-one, confirming their structures using 1D NMR and high resolution mass spectrome
2023·0citations·N. Nguyen et al.·Journal of Science and Technology Issue on Information and Communications Technology
Journal of Science and Technology Issue on Information and Communications Technology
Development and Therapeutic Implications of Tyrosine Kinase 2 Inhibitors.
Selective TYK2 inhibitors show potential for balancing efficacy and safety in treating various inflammatory and autoimmune diseases, with Deucravacitinib and ropsacitinib being approved by the FDA.
2023·8citations·Kuojun Zhang et al.·Journal of medicinal chemistry
Journal of medicinal chemistry
Discovery of a Potent and Subtype-Selective TYK2 Degrader Based on an Allosteric TYK2 Inhibitor.
TYK2 degraders, based on an allosteric TYK2 inhibitor, show potential for treating autoimmune diseases by targeting TYK2 degradation.
2022·7citations·Jun Kato et al.·Bioorganic & medicinal chemistry letters
Bioorganic & medicinal chemistry letters
Green synthesis, structure optimization and biological evalution of Rhopaladins’ analog 2–styryl–5-oxopyrrolidine-2- carboxamide RPDPRH on CaSki cells
RPDPRH shows potential as an effective agent against cervical cancer by inhibiting proliferation, inducing apoptosis, and down-regulating HPV E6/E7 mRNA expression.
2022·0citations·L. Ke et al.·Frontiers in Chemistry
Frontiers in Chemistry
Double drugging of prolyl-tRNA synthetase provides a new paradigm for anti-infective drug development
Halofuginone and L95 effectively target Toxoplasma gondii's prolyl-tRNA synthetase, providing a new approach for anti-infective drug development.
2022·13citations·Y. Manickam et al.·PLoS Pathogens
PLoS Pathogens